COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy (LYMPHOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01841814
Recruitment Status : Withdrawn (physician departure)
First Posted : April 29, 2013
Last Update Posted : December 5, 2016
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:
The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Osteoporosis Radiation: Bone densitometry. Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.
Study Start Date : April 2013
Actual Primary Completion Date : April 2013
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: lymphoma Radiation: Bone densitometry.

Primary Outcome Measures :
  1. Measurement of bone mineral density (BMD). [ Time Frame: Change from Baseline of bone mineral density at 12 months. ]
    Patients will have a review of bone densitometry.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects aged 18 to 80 with lymphoma,
  • Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
  • Patients who have not yet started their chemotherapy or who have started for less than a month
  • Patient has signed informed consent.

Exclusion Criteria:

  • Pathological fractures at the time of initial diagnosis of lymphoma,
  • Compression of neurological epidural,
  • Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
  • Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
  • Radiotherapy to the lumbar spine or hip studied,
  • Location of bone lymphoma in the lumbar spine or hip studied,
  • History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
  • A person incapable of giving consent personally,
  • Pregnant or breastfeeding women,
  • Protected Person (under guardianship)
  • Patient not affiliated with a social security system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01841814

Layout table for location information
Gandhi DAMAJ
Amiens, Picardie, France, 80054
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Layout table for investigator information
Principal Investigator: Gandhi DAMAJ, Doctor CHU d'Amiens France
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens Identifier: NCT01841814    
Other Study ID Numbers: PI11-DR-DAMAJ
First Posted: April 29, 2013    Key Record Dates
Last Update Posted: December 5, 2016
Last Verified: December 2016
Keywords provided by Centre Hospitalier Universitaire, Amiens:
Patient with
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases